Sutro Biopharma Inc.
Research Sutro Biopharma Inc. (S090) on Bullrun: market cap EUR 298.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerS090
- ExchangeF
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 298.46M
- Financial periodQ1 2026
- RevenueUSD 14.52M
- Net income-USD 38.48M
- Free cash flow-USD 42.27M
Valuation Snapshot
latest market cap is EUR 298.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 102.48M | -USD 191.09M | -USD 178.93M | n/a | n/a | USD 58.13M | USD 15.67M | -USD 132.45M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 298.46M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Sutro Biopharma Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Sutro Biopharma Inc.'s market cap?
Sutro Biopharma Inc.'s market capitalization is EUR 298.46M.
What does Sutro Biopharma Inc. do?
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer.